Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT003/PT005/PT001 vs placebo in moderate to very severe COPD
jRCT2080224018Phase 3
- Sponsor
- Pearl Therapeutics
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone propionate + formoterol fumarate + glycopyrronium bromide, formoterol and glycopyrronium in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Pearl Therapeutics.
02
Drugs
fluticasone propionate + formoterol fumarate + glycopyrronium bromideformoterolglycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2080224018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224018.